First Eagle Investment Management’s Summit Therapeutics SMMT Stock Holding History

First Eagle Investment Management’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-194,900	Closed	-$478K	–	181
2018 Q2	$478K	Hold	194,900	–	–	﹤0.01%	163
2018 Q1	$2.51M	Hold	194,900	–	–	0.01%	152
2017 Q4	$2.16M	Buy	194,900 +20,000	+11%	+$223K	0.01%	195
2017 Q3	$2.19M	Hold	174,900	–	–	﹤0.01%	199
2017 Q2	$1.92M	Hold	174,900	–	–	﹤0.01%	202
2017 Q1	$2.33M	Sell	174,900 -100	-0.1%	-$1.16K	0.01%	197
2016 Q4	$1.5M	Hold	175,000	–	–	﹤0.01%	207
2016 Q3	$1.61M	Hold	175,000	–	–	﹤0.01%	227
2016 Q2	$1.38M	Hold	175,000	–	–	﹤0.01%	235
2016 Q1	$1.23M	Hold	175,000	–	–	﹤0.01%	225
2015 Q4	$2.01M	Hold	175,000	–	–	0.01%	200
2015 Q3	$1.82M	Hold	175,000	–	–	﹤0.01%	201
2015 Q2	$1.94M	Hold	175,000	–	–	﹤0.01%	203
2015 Q1	$2.17M	Buy	+175,000	New	+$1.98M	0.01%	204

Other funds holding SMMT

LPU

Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

FFW

Fusion Family Wealth Woodbury, New York $1.34B AUM 18.88% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

First Eagle Investment Management's SMMT Position: Q3 2018 in Review

First Eagle Investment Management sold out of Summit Therapeutics (SMMT) in Q3 2018, closing a stake of 194,900 shares — an estimated $478K sold.

First Eagle Investment Management first reported a position in SMMT in Q1 2015 and held it in 14 quarters. The position peaked at $2.51M in Q1 2018. 14 funds tracked by Wall St. Rank hold SMMT as of Q3 2018.

First Eagle Investment Management reported no remaining Summit Therapeutics position as of Q3 2018 after selling out during the quarter.
First Eagle Investment Management sold 194,900 Summit Therapeutics shares in Q3 2018, an estimated $478K.
First Eagle Investment Management first reported a position in Summit Therapeutics in Q1 2015 and held it in 14 quarters.
First Eagle Investment Management's Summit Therapeutics position peaked at $2.51M in Q1 2018.
14 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2018.

Based on First Eagle Investment Management's 13F filing for Q3 2018, filed 13 Nov 2018.